Evidence map›Paper›PMID 23660970›Full record

SynthesisHarvard review of psychiatry

Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: a systematic review.

Suzanne M Czerniak, Elif M Sikoglu, Jean A King, David N Kennedy, Eric Mick, Jean Frazier, Constance M Moore

Registry-linked trialAbstract readSystematic Review
In one paragraph

Synthesis in Harvard review of psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02695355 (Pediatric Attention Deficit Hyperactivity Disorder), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02695355 phase2completednot on this map

Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials

TypeinterventionalSponsorOstfold Hospital TrustRan2006 to 2015Enrolled87ConditionsAttention Deficit Hyperactivity DisorderArmsMethylphenidate (MPH)
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Lingual Dyskinesia Developing after the First Dose of Methylphenidate Treatment in a Child with Neurodevelopmental Disorders: Genetic Predispositions.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Article
  8. Article
  9. Neural basis for individual differences in the attention-enhancing effects of methylphenidate.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Inflammation, Dopaminergic Brain and Bilirubin.International journal of molecular sciences · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suzanne M CzerniakUniversity of Massachusetts Medical School, 303 Belmont St., Worcester, MA 01604, USA. Constance.Moore@umassmed.edu
Elif M Sikoglu
Jean A King
David N Kennedy
Eric Mick
Jean Frazier
Constance M Moore

Funding

TISSUE CULTURE CORE FACILITYP30HD004147 · NICHD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CURTIN, CAROL · 1985 to 2014
$9.1M
Exposing the Deep Content of the Publication: Knowledge Extraction for Neuroimaging in Child PsychiatryR01MH083320 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FRAZIER, JEAN A, KENNEDY, DAVID NELSON · 2009 to 2020
$6.3M
Glutamine and Glutamate in Children and Adolescents with Bipolar DisorderR01MH073998 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MOORE, CONSTANCE M · 2008 to 2012
$1.5M
NICHD NIH HHS P30 HD004147NIMH NIH HHS R01 MH073998NIMH NIH HHS R01 MH083320
6 · The paper itself

Abstract

objectiveAttention-deficit/hyperactivity disorder (ADHD) is a psychiatric disorder affecting 5% of children. Methylphenidate (MPH) is a common medication for ADHD. Studies examining MPH's effect on pediatric ADHD patients' brain function using functional magnetic resonance imaging (fMRI) have not been compiled. The goals of this systematic review were to determine (1) which areas of the brain in pediatric ADHD patients are modulated by a single dose of MPH, (2) whether areas modulated by MPH differ by task type performed during fMRI data acquisition, and (3) whether changes in brain activation due to MPH relate to clinical improvements in ADHD-related symptoms.

methodsWe searched the electronic databases PubMed and PsycINFO (1967-2011) using the following terms: ADHD AND (methylphenidate OR MPH OR ritalin) AND (neuroimaging OR MRI OR fMRI OR BOLD OR event related), and identified 200 abstracts, 9 of which were reviewed based on predefined criteria.

resultsIn ADHD patients the middle and inferior frontal gyri, basal ganglia, and cerebellum were most often affected by MPH. The middle and inferior frontal gyri were frequently affected by MPH during inhibitory control tasks. Correlation between brain regions and clinical improvement was not possible due to the lack of symptom improvement measures within the included studies.

conclusionsThroughout nine task-based fMRI studies investigating MPH's effect on the brains of pediatric patients with ADHD, MPH resulted in increased activation within frontal lobes, basal ganglia, and cerebellum. In most cases, this increase "normalized" activation of at least some brain areas to that seen in typically developing children.

Indexed as

Functional NeuroimagingMagnetic Resonance ImagingAdolescentAttention Deficit Disorder with HyperactivityBasal GangliaBrainCentral Nervous System StimulantsCerebellumChildFemaleFrontal LobeHumansMaleMethylphenidateCentral Nervous System StimulantsMethylphenidate

Identifiers

PMID23660970
PMCPMC4103657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.